Tag: TCT 2016

The implications of ABSORB II three-year results for the future of...

The idea of a fully bioresorbable scaffold is attractive as the need for mechanical support for the healing artery after percutaneous coronary intervention (PCI)...

Medinol reports positive clinical results for Elunir elastomer-coated drug-eluting stent

Twelve-month clinical results from Medinol’s BIONICS study have demonstrated that the company’s Elunir stent has a good safety profile, among other positive results. The study...

TCT 2016: Three-year data fail to show Absorb to be superior...

According to the three-year results of the ABSORB II trial, a bioresorbable vascular scaffold (Absorb, Abbott Vascular) does not provide superior vasomotor reactivity than...

TCT 2016: Different endpoints may have led to different outcomes for...

Two randomised controlled trials have produced what appears to be conflicting results for how left main percutaneous coronary intervention (PCI) compares with coronary artery...

TCT 2016: Positive data for transcatheter tricuspid repair with Trialign

Mitralign presented 30-day data from the SCOUT I study, which designed to evaluate the performance of its Trialign system for tricuspid repair, at the...

TCT 2016: Transfemoral TAVI improves quality of life in intermediate-risk patients

Data presented at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October–2 November, Washington, DC, USA) indicate that intermediate-risk patients who undergo transcatheter aortic...

TCT 2016: “Excellent” rates of late lumen loss with Desolve bioresorbable...

Six-month clinical data for Elixir Medical’s bioresorbable scaffold (Desolve) were presented at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October–2 November, Washington, DC,...

TCT 2016: Cardiovascular System initiates largest ever randomised trial of coronary...

At the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October–2 November, Washington, DC, USA), Cardiovascular Systems debuted the design of its new ECLIPSE clinical...

TCT 2016: Women and minorities have a significantly higher risk...

Data from the PLATINUM DIVERSITY trial, which was presented at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October–2 November, Washington DC, USA), indicates...

TCT 2016: SENTINEL trial fails to meet overall primary efficacy endpoint...

The SENTINEL trial, which was presented at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October-2 November, Washington , DC, USA) today, has not...

TCT 2016: Physicians discuss their positive experiences of using a metallic...

At a symposium at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October-2 November, Washington, DC, USA), physicians discussed their first experiences with a...

TCT 2016: First-in-human data shows Medtronic’s drug-filled stent to be non-inferior...

Results of the REVELUTION study, simultaneously presented at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October-2 November, Washington, DC, USA) and published in...

TCT 2016: Positive real-world data for CoreValve Evolut R presented

Today, Medtronic presented new positive data from two large registries aimed at evaluating 30-day clinical performance outcomes for its self-expanding, recapturable and repositionable CoreValve...

TCT 2016: FDA approve Amplatzer PFO occluder device ahead of first...

The FDA has approved St Jude Medical’s Amplatzer patent foramen ovale (PFO) occluder device for the prevention of stroke. Announced on 28 October, this...

TCT 2016: All comers study finds no differences between Orsiro, Synergy...

BIO-RESORT, presented at TCT today during a late-breaking trial session, has found no significant differences at one year between Medtronic's Resolute Integrity (a durable...

TCT 2016: ILUMEN III shows some advantages with OCT

ILUMEN III, the first late-breaking to be presented at the 2016 Transcatheter Cardiovascular Therapeutics meeting (29 October-2 November, Washington, DC, USA), has met its...

CorPath GRX robotic system receives FDA 510(k) clearance

Corindus Vascular Robotics has received 510(k) clearance from the FDA for its CorPath GRX, the second generation of its CorPath vascular robotic system. A...

TCT 2016: 30-day patient data from SCOUT I study to be...

Mitralign is to outline data for its Trialign tricuspid repair system at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October–2 November, Washington, DC,...

TCT 2016: Philips showcases its latest suite of image guidance solutions...

The latest image guidance solutions of Philips will be featured at Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October–2 November, Washington, DC).  The company, according...

TCT 2016: CeloNova BioSciences announces key activities

CeloNova BioSciences has provided details of its activities at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October—2 November, Washington, DC, USA). A press...

TCT 2016: St Jude Medical to highlight latest cardiovascular portfolio

New data for St Jude Medical’s devices and technologies will be presented during late-breaking clinical trial presentations at the 2016 Transcatheter Cardiovascular Therapeutics (TCT)...

TCT 2016: First live case featuring Desolve NXT scaffold to be...

Elixir Medical has announced that it will showcase the first live case demonstration by transmission in the USA of its Desolve NXT novolimus-eluting bioresorbable...

TCT 2016: Breakfast symposium to explore robotic therapy in interventional cardiology

Corindus Vascular Robotics is to host a breakfast symposium entitled “Robotic Therapy—current Applications & Future Vision” on 31 October at 7.00am at the 2016...

TCT 2016: Tryton Medical to hold clinical symposium on treatment of...

Tryton Medical has announced that it will be sponsoring a clinical symposium and exhibiting at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October–2...